A majority of life science firms are standing on the edge of the patent cliff and their drug pipelines are experiencing acute scarcity. This is making them seek out partners for mergers & acquisition (M&A). Also read: • Why did mergers... Read more
Sinopharm, a dominant name in the distribution of pharmaceutical and healthcare products in China, continues to grab a large... Read more
Australia emerged as the third largest country in terms of the total revenue generated by companies during the calendar year... Read more
India emerged as the second largest country in terms of the total revenue generated by companies during the calendar year 2012 in the recent... Read more
China emerged as the third country in terms of the total revenue generated by companies during the calendar year 2012 in the recent BioSpectrum... Read more
The annual list of Asia's fastest growing pharma companies, compiled painstakingly by the BioSpectrum Asia team, is out. A remarkable aspect... Read more
Shortage of skills and qualification among life science professionals to pursue risk laden activities is proving to be a hurdle for Asia... Read more
In the biomedical sector, the combination of latest technology and a strong business model is considered to be ideal. Theoretically, the... Read more
With rapid growth of life sciences industry in Asia, we have seen many success stories over the last decade. However, any period of extensive... Read more
A majority of life science firms are standing on the edge of the patent cliff and their drug pipelines are experiencing acute scarcity.... Read more
Most pharmaceutical companies are sitting on the patent cliff and their drug pipelines are facing severe exhaustion. The big players of... Read more
The global bioscience industry, in 2012, reported 450 mergers and acquisitions (M&A) transactions valued at $67 billion, which is about... Read more
Survey Box